BackUnity Biotechnology Overview

Unity Biotechnology Accounts Payable

Unity Biotechnology's accounts payable is $1.8M.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$1.76M
25.97% YoYΔ $363000.00 vs prior year quarter

Peer average

Loading

Unity Biotechnology Accounts Payable History

Loading

Unity Biotechnology vs. peers: Accounts Payable Comparison

Loading

Unity Biotechnology Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Unity Biotechnology (UBX) FAQ

As of the most recent data (March 2025), UBX shows a accounts payable of $1.8M. That compares with $1.4M in the prior-year period — up 26.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, UBX's accounts payable is now $1.8M (was $1.4M) — a 26.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Unity Biotechnology is outperforming or lagging.

Tracking UBX's accounts payable over time shows whether Unity Biotechnology is scaling, shrinking, or reshaping that part of the business. The current reading is $1.8M That compares with $1.4M in the prior-year period — up 26.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Unity Biotechnology's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $1.8M) with ownership activity and broader fundamentals.

Unity Biotechnology's accounts payable is $1.8M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.